Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-11-06FDA Approved: METOCLOPRAMIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva's metoclopramide product, updating its regulatory status as a marketed generic drug.
-
CLINICAL_TRIALS trial_result · 2009-11-06Clinical Trial Update: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) [Phase 3]
This document reports the completion of a Phase 3 clinical trial evaluating aprepitant for the prevention of chemotherapy-induced nausea and…
-
CLINICAL_TRIALS trial_result · 2009-10-23Clinical Trial Update: A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED) [Phase 2]
A multicenter randomized Phase 2 trial evaluating SCH 619734 for chemotherapy-induced nausea and vomiting has completed.
-
FDA approval · 2009-09-25FDA Approved: ONDANSETRON — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original ANDA for ondansetron from Heritage Pharmaceuticals (Avet) as a generic antiemetic to prevent nausea and vomiting du…
-
FDA approval · 2009-09-04FDA Approved: REGLAN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for REGLAN (metoclopramide hydrochloride), enabling changes under a supplemen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2009-07-28Clinical Trial Update: A Study to Assess the Anti-Emetic Efficacy of Ginger in Children and Adolescents Receiving Chemotherapy [Phase 3]
This is a Phase 3 clinical trial evaluating whether ginger can reduce chemotherapy-induced nausea and vomiting in children and adolescents. …
-
FDA approval · 2009-07-21FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC.
-
FDA approval · 2009-06-30FDA Approved: METOCLOPRAMIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for metoclopramide.
-
FDA approval · 2009-02-02FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC to update the labeling for prevention of che…
-
FDA approval · 2009-02-02FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) by Merck Sharp & Dohme LLC.
-
FDA approval · 2008-12-05FDA Approved: CESAMET — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for CESAMET (nabilone) from Bausch Health US LLC. The action updates the product labeling per th…
-
FDA approval · 2008-11-18FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) by Merck Sharp & Dohme LLC. The approval expands the labeling to include …
-
FDA approval · 2008-10-28FDA Approved: METOCLOPRAMIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for metoclopramide from ANI Pharmaceuticals, Inc., for an already approved generic product. This…
-
FDA approval · 2008-10-23FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
FDA approved a supplemental application for Ondansetron from AvKARE under ANDA078152, authorizing the generic product's marketing.
-
FDA approval · 2008-09-12FDA Approved: SANCUSO — Original Application (Cumberland Pharmaceuticals Inc.)
The FDA approved SANCUSO (granisetron) under an original NDA by Cumberland Pharmaceuticals Inc. for the prevention of chemotherapy-induced n…
-
FDA approval · 2008-08-18FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for ondansetron from Glenmark Pharmaceuticals Inc., USA, for a generic product; this action may invo…
-
FDA approval · 2008-08-18FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
FDA approved a supplemental application for AvKARE's ondansetron (ANDA 078152), resulting in labeling updates for the product. The action co…
-
FDA approval · 2008-06-30FDA Approved: GRANISETRON — Original Application (Fresenius Kabi USA, LLC)
FDA approved an original application for granisetron hydrochloride (granisetron) by Fresenius Kabi USA, LLC, a generic antiemetic.
-
FDA approval · 2008-06-27FDA Approved: DRONABINOL — Original Application (Rhodes Pharmaceuticals L.P.)
FDA approves Rhodes Pharmaceuticals' original application for dronabinol (a generic), with indications for chemotherapy-induced nausea and v…
-
CLINICAL_TRIALS trial_result · 2008-04-25Clinical Trial Update: An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients [Phase 2]
Phase 2 study completed evaluating Palonosetron for efficacy and safety in preventing chemotherapy-induced nausea and vomiting in Chinese ca…
-
FDA approval · 2008-04-23FDA Approved: ONDANSETRON HYDROCHLORIDE — Original Application (Onesource Specialty Pharma Limited)
FDA approved the original application for ondansetron hydrochloride (generic) from Onesource Specialty Pharma Limited.
-
FDA approval · 2008-04-23FDA Approved: ONDANSETRON HYDROCHLORIDE — Original Application (Onesource Specialty Pharma Limited)
FDA approved ondansetron hydrochloride under an Original Application (ANDA078257) for use as an antiemetic. The generic product is developed…
-
CLINICAL_TRIALS trial_result · 2008-04-03Clinical Trial Update: Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting [Phase 3]
Phase 3 trial comparing dronabinol with standard ondansetron therapy to prevent delayed-onset chemotherapy-induced nausea and vomiting has c…
-
FDA approval · 2008-02-29FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Cipla USA Inc.)
FDA granted supplemental approval for palonosetron hydrochloride from Cipla USA Inc. under NDA 021372.
-
FDA approval · 2008-02-13FDA Approved: GRANISETRON HYDROCHLORIDE — Original Application (Bionpharma Inc.)
FDA approved the original application for granisetron hydrochloride by Bionpharma Inc., enabling the generic product. Granisetron hydrochlor…